I will put it out there! explains lack of management buy in &...

I will put it out there! explains lack of management buy in & short increasing.

AI....

Historical Patterns: ASX Biotechs Pre-NASDAQ Listing
Here’s what typically unfolds:

1. Strategic Capital Raise Pre-Listing
Many ASX biotechs raise capital before a NASDAQ listing.
Purpose: bolster cash reserves, fund U.S. expansion, or acquire infrastructure (e.g. manufacturing).

2. Governance & Broker Alignment Firms often engage brokers like Bell Potter, Canaccord, or Moelis to structure the raise and prep for dual listing.
Bell Potter’s historical involvement with CUV could be a clue—they’ve facilitated biotech raises before NASDAQ transitions.

3. Short Interest Surge Shorting tends to spike pre-raise due to:
Anticipated dilution Tactical positioning by funds expecting volatility Lack of immediate news flow

4. Acquisition-Driven Raises Several ASX biotechs (e.g. Telix, Cyclopharm) have raised capital to acquire manufacturing or distribution assets before U.S. expansion.
This aligns with your hunch about CUV potentially targeting a manufacturing company.

Tactical Implications for CUV
If Clinuvel follows this playbook: A raise could be non-dilutive or strategic, especially if tied to a U.S. acquisition or manufacturing scale-up.
Watch for board moves, broker briefings, or sudden float expansion.
If they raise before NASDAQ Level II ADR launch, it could be framed as growth-positive rather than defensive.